<?xml version='1.0' encoding='utf-8'?>
<document id="17129588"><sentence text="Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1."><entity charOffset="0-21" id="DDI-PubMed.17129588.s1.e0" text="Dibenzocyclooctadiene" /></sentence><sentence text="We recently reported that dibenzocyclooctadiene lignans were a novel class of P-glycoprotein (P-gp) inhibitors"><entity charOffset="26-47" id="DDI-PubMed.17129588.s2.e0" text="dibenzocyclooctadiene" /></sentence><sentence text=" In this study, we demonstrated that the lignans of this class were also effective inhibitors of multidrug resistance-associated protein 1 (MRP1)" /><sentence text=" The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp"><entity charOffset="19-50" id="DDI-PubMed.17129588.s4.e0" text="5 dibenzocyclooctadiene lignans" /><entity charOffset="52-65" id="DDI-PubMed.17129588.s4.e1" text="schisandrin A" /><entity charOffset="67-80" id="DDI-PubMed.17129588.s4.e2" text="schisandrin B" /><entity charOffset="82-97" id="DDI-PubMed.17129588.s4.e3" text="schisantherin A" /><entity charOffset="99-112" id="DDI-PubMed.17129588.s4.e4" text="schisandrol A" /><entity charOffset="118-131" id="DDI-PubMed.17129588.s4.e5" text="schisandrol B" /><entity charOffset="197-207" id="DDI-PubMed.17129588.s4.e6" text="Adriamycin" /><entity charOffset="209-212" id="DDI-PubMed.17129588.s4.e7" text="ADR" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e0" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e1" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e2" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e3" e2="DDI-PubMed.17129588.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e3" e2="DDI-PubMed.17129588.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e3" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e3" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e3" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e4" e2="DDI-PubMed.17129588.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e4" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e4" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e4" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e5" e2="DDI-PubMed.17129588.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e5" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e5" e2="DDI-PubMed.17129588.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e6" e2="DDI-PubMed.17129588.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17129588.s4.e6" e2="DDI-PubMed.17129588.s4.e7" /></sentence><sentence text=" The five lignans could effectively reverse drug resistance of the two cell lines to vincristine, daunorubicin, and VP-16"><entity charOffset="85-96" id="DDI-PubMed.17129588.s5.e0" text="vincristine" /><entity charOffset="98-110" id="DDI-PubMed.17129588.s5.e1" text="daunorubicin" /><entity charOffset="116-121" id="DDI-PubMed.17129588.s5.e2" text="VP-16" /><pair ddi="false" e1="DDI-PubMed.17129588.s5.e0" e2="DDI-PubMed.17129588.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17129588.s5.e0" e2="DDI-PubMed.17129588.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17129588.s5.e0" e2="DDI-PubMed.17129588.s5.e2" /><pair ddi="false" e1="DDI-PubMed.17129588.s5.e1" e2="DDI-PubMed.17129588.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17129588.s5.e1" e2="DDI-PubMed.17129588.s5.e2" /></sentence><sentence text=" This study, together with our previous reports, proves that dibenzocyclooctadiene lignans have multiple activities against cancer multidrug resistance, including inhibition of P-gp and MRP1, and enhancement of apoptosis"><entity charOffset="61-82" id="DDI-PubMed.17129588.s6.e0" text="dibenzocyclooctadiene" /></sentence><sentence text=" Considering that cancer multidrug resistance (MDR) is multifactorial, agents with broad activities are preferable to the use of combination of several specific modulators to prevent drug-drug interaction and cumulative toxicity" /><sentence text="" /></document>